C

Coya Therapeutics Inc
NASDAQ:COYA

Watchlist Manager
Coya Therapeutics Inc
NASDAQ:COYA
Watchlist
Price: 5.55 USD 2.97% Market Closed
Market Cap: 116.1m USD

Wall Street
Price Targets

COYA Price Targets Summary
Coya Therapeutics Inc

Wall Street analysts forecast COYA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for COYA is 16.39 USD with a low forecast of 14.14 USD and a high forecast of 18.9 USD.

Lowest
Price Target
14.14 USD
155% Upside
Average
Price Target
16.39 USD
195% Upside
Highest
Price Target
18.9 USD
241% Upside
Coya Therapeutics Inc Competitors:
Price Targets
SPRY
ARS Pharmaceuticals Inc
147% Upside
6855
Ascentage Pharma Group International
90% Upside
SVRA
Savara Inc
64% Upside
BVXP
Bioventix PLC
121% Upside
IMMU
Mendus AB (publ)
227% Upside
ARWR
Arrowhead Pharmaceuticals Inc
10% Downside
ELDN
Eledon Pharmaceuticals Inc
420% Upside
RCUS
Arcus Biosciences Inc
42% Upside

Revenue
Forecast

Revenue Estimate
Coya Therapeutics Inc

The compound annual growth rate of Coya Therapeutics Inc's revenue for the next 4 years is 38%.

N/A
Past Growth
38%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Coya Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Coya Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-57%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is COYA's stock price target?
Price Target
16.39 USD

According to Wall Street analysts, the average 1-year price target for COYA is 16.39 USD with a low forecast of 14.14 USD and a high forecast of 18.9 USD.

What is Coya Therapeutics Inc's Revenue forecast?
Projected CAGR
38%

The compound annual growth rate of Coya Therapeutics Inc's revenue for the next 4 years is 38%.

Back to Top